Research Articles
Research articles concerning NAFLD are extracted from PubMed. For each individual article, related therapeutic strategies, targets, drugs and associated diseases in NAFLDkb are presented with knowledge graphs.
stats1
stats2
stats3
stats4
Search for:
lipogenesis1889 records.
| Article ID | PMID | Source | Title | Publish Year | |
|---|---|---|---|---|---|
| A09881 | 31576092 | World J Gastroenterol | Zinc-α2-glycoprotein 1 attenuates non-alcoholic fatty liver disease by negatively regulating tumour necrosis factor-α. | 2019 | Details |
| A09894 | 31571145 | Arch Pharm Res | Molecular insights into the role of mitochondria in non-alcoholic fatty liver disease. | 2019 | Details |
| A09895 | 31570772 | Lab Invest | Cannabinoid receptor 1 knockout alleviates hepatic steatosis by downregulating perilipin 2. | 2019 | Details |
| A09923 | 31558861 | World J Gastroenterol | Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-κB signaling pathways. | 2019 | Details |
| A09933 | 31554932 | Nat Rev Endocrinol | The regulation of hepatic fatty acid synthesis and partitioning: the effect of nutritional state. | 2019 | Details |
| A09972 | 31539884 | J Physiol Pharmacol | Diverse inhibition of forkhead box O1 activity by linoleic acid isomers - potential role in lipid metabolism in HepG2 cells and livers of C57BL/6J mice. | 2019 | Details |
| A09999 | 31530849 | Sci Rep | Controlling Obesity and Metabolic Diseases by Hydrodynamic Delivery of a Fusion Gene of Exendin-4 and α1 Antitrypsin. | 2019 | Details |
| A10002 | 31529722 | Hepatology | Hepatocyte ELOVL Fatty Acid Elongase 6 Determines Ceramide Acyl-Chain Length and Hepatic Insulin Sensitivity in Mice. | 2020 | Details |
| A10031 | 31519114 | Expert Opin Investig Drugs | GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH). | 2019 | Details |
| A10063 | 31505325 | Redox Biol | Peroxiredoxin 5 ameliorates obesity-induced non-alcoholic fatty liver disease through the regulation of oxidative stress and AMP-activated protein kinase signaling. | 2019 | Details |
| A10073 | 31501836 | Food Funct | High-fat diet induces mouse liver steatosis with a concomitant decline in energy metabolism: attenuation by eicosapentaenoic acid (EPA) or hydroxytyrosol (HT) supplementation and the additive effects upon EPA and HT co-administration. | 2019 | Details |
| A10085 | 31493478 | Life Sci | Strength training reduces lipid accumulation in liver of obese Wistar rats. | 2019 | Details |
| A10099 | 31484323 | Nutrients | Indole-3-Acetic Acid Alleviates Nonalcoholic Fatty Liver Disease in Mice via Attenuation of Hepatic Lipogenesis, and Oxidative and Inflammatory Stress. | 2019 | Details |
| A10131 | 31473346 | Biochim Biophys Acta Mol Cell Biol Lipids | Exercise regulates lipid droplet dynamics in normal and fatty liver. | 2019 | Details |
| A10132 | 31473320 | Metab Eng | Determining contributions of exogenous glucose and fructose to de novo fatty acid and glycerol synthesis in liver and adipose tissue. | 2019 | Details |
| A10134 | 31472955 | Biochem Biophys Res Commun | Vitexin alleviates non-alcoholic fatty liver disease by activating AMPK in high fat diet fed mice. | 2019 | Details |
| A10142 | 31470518 | Biomolecules | Beyond the Scavenging of Reactive Oxygen Species (ROS): Direct Effect of Cerium Oxide Nanoparticles in Reducing Fatty Acids Content in an In Vitro Model of Hepatocellular Steatosis. | 2019 | Details |
| A10144 | 31470288 | Nutr Res | Gnotobiotic mice inoculated with Firmicutes, but not Bacteroidetes, deteriorate nonalcoholic fatty liver disease severity by modulating hepatic lipid metabolism. | 2019 | Details |
| A10163 | 31463669 | J Nat Med | Cynandione A from Cynanchum wilfordii inhibits hepatic de novo lipogenesis by activating the LKB1/AMPK pathway in HepG2 cells. | 2019 | Details |
| A10171 | 31455870 | Int J Obes (Lond) | Specific diacylglycerols generated by hepatic lipogenesis stimulate the oncogenic androgen receptor activity in male hepatocytes. | 2019 | Details |
| A10174 | 31454158 | Mol Nutr Food Res | Tomatidine Reduces Palmitate-Induced Lipid Accumulation by Activating AMPK via Vitamin D Receptor-Mediated Signaling in Human HepG2 Hepatocytes. | 2019 | Details |
| A10212 | 31430456 | Eur J Pharmacol | Pinolenic acid ameliorates oleic acid-induced lipogenesis and oxidative stress via AMPK/SIRT1 signaling pathway in HepG2 cells. | 2019 | Details |
| A10214 | 31430204 | Am J Physiol Endocrinol Metab | Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway. | 2019 | Details |
| A10227 | 31421115 | Chem Biol Interact | Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner. | 2019 | Details |
| A10234 | 31419466 | Mol Cell Endocrinol | Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress. | 2019 | Details |
| A10240 | 31415794 | Mol Cell Endocrinol | Creosote bush-derived NDGA attenuates molecular and pathological changes in a novel mouse model of non-alcoholic steatohepatitis (NASH). | 2019 | Details |
| A10264 | 31406506 | J Biol Eng | Targeting CYP4A attenuates hepatic steatosis in a novel multicellular organotypic liver model. | 2019 | Details |
| A10280 | 31401389 | Cell Calcium | Deranged hepatocyte intracellular Ca2+ homeostasis and the progression of non-alcoholic fatty liver disease to hepatocellular carcinoma. | 2019 | Details |
| A10292 | 31397492 | Clin Exp Pharmacol Physiol | Insulin-like growth factor binding protein 7 accelerates hepatic steatosis and insulin resistance in non-alcoholic fatty liver disease. | 2019 | Details |
| A10304 | 31392349 | Cell Mol Life Sci | Lipophagy mediated carbohydrate-induced changes of lipid metabolism via oxidative stress, endoplasmic reticulum (ER) stress and ChREBP/PPARγ pathways. | 2019 | Details |
| A10325 | 31387306 | Int J Mol Sci | High-Fat Feeding in Time-Dependent Manner Affects Metabolic Routes Leading to Nervonic Acid Synthesis in NAFLD. | 2019 | Details |
| A10338 | 31384531 | Acta Pharm Sin B | Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters. | 2019 | Details |
| A10361 | 31374969 | Nutrients | Melon GliSODin® Prevents Diet-Induced NASH Onset by Reducing Fat Synthesis and Improving Liver Function. | 2019 | Details |
| A10384 | 31361524 | FASEB J | Maslinic acid protects against obesity-induced nonalcoholic fatty liver disease in mice through regulation of the Sirt1/AMPK signaling pathway. | 2019 | Details |
| A10420 | 31343116 | Obesity (Silver Spring) | Novel Strategies to Treat Hepatic Steatosis and Steatohepatitis. | 2019 | Details |
| A10425 | 31341532 | Oxid Med Cell Longev | Dietary Glycotoxins Impair Hepatic Lipidemic Profile in Diet-Induced Obese Rats Causing Hepatic Oxidative Stress and Insulin Resistance. | 2019 | Details |
| A10442 | 31336149 | Biochim Biophys Acta Mol Basis Dis | The adipokine sFRP4 induces insulin resistance and lipogenesis in the liver. | 2019 | Details |
| A10456 | 31330134 | Metabolism | AKR1D1 is a novel regulator of metabolic phenotype in human hepatocytes and is dysregulated in non-alcoholic fatty liver disease. | 2019 | Details |
| A10471 | 31323923 | Toxins (Basel) | Sub-Chronic Microcystin-LR Liver Toxicity in Preexisting Diet-Induced Nonalcoholic Steatohepatitis in Rats. | 2019 | Details |
| A10474 | 31322255 | Mol Med Rep | Adenovirus‑mediated overexpression of bone morphogenetic protein‑9 promotes methionine choline deficiency‑induced non‑alcoholic steatohepatitis in non‑obese mice. | 2019 | Details |
| A10497 | 31311301 | FASEB J | Long noncoding RNA FLRL2 alleviated nonalcoholic fatty liver disease through Arntl-Sirt1 pathway. | 2019 | Details |
| A10506 | 31309533 | FEBS Lett | Chronic exposure to Pb2+ perturbs ChREBP transactivation and coerces hepatic dyslipidemia. | 2019 | Details |
| A10509 | 31308686 | Nutr Metab Insights | Potential Mechanisms Influencing the Inverse Relationship Between Cannabis and Nonalcoholic Fatty Liver Disease: A Commentary. | 2019 | Details |
| A10514 | 31307592 | Adv Pharmacol | Drug-induced liver injury in obesity and nonalcoholic fatty liver disease. | 2019 | Details |
| A10519 | 31305201 | Metab Syndr Relat Disord | The Effect of Low Glycemic Index and Glycemic Load Diets on Hepatic Fat Mass, Insulin Resistance, and Blood Lipid Panels in Individuals with Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A10523 | 31301418 | Life Sci | (5R)-5-hydroxytriptolide ameliorates liver lipid accumulation by suppressing lipid synthesis and promoting lipid oxidation in mice. | 2019 | Details |
| A10547 | 31293337 | World J Gastroenterol | Biomarkers and subtypes of deranged lipid metabolism in non-alcoholic fatty liver disease. | 2019 | Details |
| A10565 | 31288993 | Mol Metab | GDF10 blocks hepatic PPARγ activation to protect against diet-induced liver injury. | 2019 | Details |
| A10586 | 31280138 | Phytomedicine | Anti-hepatic steatosis activity of Sicyos angulatus extract in high-fat diet-fed mice and chemical profiling study using UHPLC-qTOF-MS/MS spectrometry. | 2019 | Details |
| A10591 | 31278754 | J Physiol | Liver sympathetic denervation reverses obesity-induced hepatic steatosis. | 2019 | Details |
| A10601 | 31275407 | Evid Based Complement Alternat Med | Pharmacological Activities of Alisma orientale against Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: Literature Review. | 2019 | Details |
| A10679 | 31239155 | Biochem Biophys Res Commun | LncRNA NEAT1-MicroRNA-140 axis exacerbates nonalcoholic fatty liver through interrupting AMPK/SREBP-1 signaling. | 2019 | Details |
| A10695 | 31233775 | J Control Release | The hepatic-targeted, resveratrol loaded nanoparticles for relief of high fat diet-induced nonalcoholic fatty liver disease. | 2019 | Details |
| A10699 | 31233505 | PLoS One | Adenovirus-mediated expression of SIK1 improves hepatic glucose and lipid metabolism in type 2 diabetes mellitus rats. | 2019 | Details |
| A10710 | 31227231 | Mol Cell | HCF-1 Regulates De Novo Lipogenesis through a Nutrient-Sensitive Complex with ChREBP. | 2019 | Details |
| A10716 | 31225503 | Cell Stress | Hepatic stress associated with pathologies characterized by disturbed glucose production. | 2019 | Details |
| A10718 | 31225456 | Cell Stress | Attenuating MKRN1 E3 ligase-mediated AMPKα suppression increases tolerance against metabolic stresses in mice. | 2018 | Details |
| A10722 | 31222048 | Nat Commun | Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis. | 2019 | Details |
| A10732 | 31217846 | Am J Transl Res | Berberine prevents non-alcoholic steatohepatitis-derived hepatocellular carcinoma by inhibiting inflammation and angiogenesis in mice. | 2019 | Details |
| A10739 | 31214287 | Nutr Res Pract | Free fatty acid-induced histone acetyltransferase activity accelerates lipid accumulation in HepG2 cells. | 2019 | Details |
| A10744 | 31213868 | Diabetes Metab Syndr Obes | The negative and detrimental effects of high fructose on the liver, with special reference to metabolic disorders. | 2019 | Details |
| A10748 | 31212314 | J Nutr | Dietary β-Cryptoxanthin Inhibits High-Refined Carbohydrate Diet-Induced Fatty Liver via Differential Protective Mechanisms Depending on Carotenoid Cleavage Enzymes in Male Mice. | 2019 | Details |
| A10749 | 31211621 | Am J Physiol Endocrinol Metab | Mouse trefoil factor 3 ameliorated high-fat-diet-induced hepatic steatosis via increasing peroxisome proliferator-activated receptor-α-mediated fatty acid oxidation. | 2019 | Details |
| A10780 | 31197036 | J Biol Chem | Enhanced acetylation of ATP-citrate lyase promotes the progression of nonalcoholic fatty liver disease. | 2019 | Details |
| A10782 | 31195981 | Mol Med | miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease. | 2019 | Details |
| A10832 | 31168625 | Carcinogenesis | Sex hormone-binding globulin suppresses NAFLD-triggered hepatocarcinogenesis after menopause. | 2019 | Details |
| A10833 | 31168511 | Hepatol Commun | Lipocalin-2 Protects Against Diet-Induced Nonalcoholic Fatty Liver Disease by Targeting Hepatocytes. | 2019 | Details |
| A10864 | 32953568 | J Tradit Complement Med | Calcium supplementation shows a hepatoprotective effect against high-fat diet by regulating oxidative-induced inflammatory response and lipogenesis activity in male rats. | 2019 | Details |
| A10874 | 31145699 | JCI Insight | A randomized 3-way crossover study indicates that high-protein feeding induces de novo lipogenesis in healthy humans. | 2019 | Details |
| A10892 | 31137047 | Planta Med | Z-ligustilide and n-Butylidenephthalide Isolated from the Aerial Parts of Angelica tenuissima Inhibit Lipid Accumulation In Vitro and In Vivo. | 2019 | Details |
| A10920 | 31123744 | Food Funct | Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway. | 2019 | Details |
| A10930 | 31115630 | Appl Microbiol Biotechnol | Lactobacillus plantarum NA136 improves the non-alcoholic fatty liver disease by modulating the AMPK/Nrf2 pathway. | 2019 | Details |
| A10941 | 31113010 | Br J Pharmacol | Bouchardatine analogue alleviates non-alcoholic hepatic fatty liver disease/non-alcoholic steatohepatitis in high-fat fed mice by inhibiting ATP synthase activity. | 2019 | Details |
| A10945 | 31110049 | J Lipid Res | FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice. | 2019 | Details |
| A10974 | 31096638 | Cells | Bone Morphogenetic Protein-8B Expression is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro. | 2019 | Details |
| A10975 | 31095863 | Mol Nutr Food Res | Trimethylamine N-Oxide Aggravates Liver Steatosis through Modulation of Bile Acid Metabolism and Inhibition of Farnesoid X Receptor Signaling in Nonalcoholic Fatty Liver Disease. | 2019 | Details |
| A10994 | 31087761 | IUBMB Life | Downregulation of hedgehog ligands in human simple steatosis may protect against nonalcoholic steatohepatitis: Is TAZ a crucial regulator? | 2019 | Details |
| A10997 | 31086120 | Int J Mol Sci | Hepatoprotective Effect of Kombucha Tea in Rodent Model of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. | 2019 | Details |
| A11006 | 31083505 | Cells | Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet. | 2019 | Details |
| A11007 | 31083413 | Int J Mol Sci | Arazyme Suppresses Hepatic Steatosis and Steatohepatitis in Diet-Induced Non-Alcoholic Fatty Liver Disease-Like Mouse Model. | 2019 | Details |
| A11017 | 31081165 | Hepatology | Hepatocyte Deletion of Triglyceride-Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice. | 2019 | Details |
| A11047 | 31069793 | J Cell Physiol | S100A16, a novel lipogenesis promoting factor in livers of mice and hepatocytes in vitro. | 2019 | Details |
| A11053 | 31064820 | Biosci Rep | LncRNA-H19 promotes hepatic lipogenesis by directly regulating miR-130a/PPARγ axis in non-alcoholic fatty liver disease. | 2019 | Details |
| A11056 | 31064103 | Nutrients | Fermented Cordyceps militaris Extract Prevents Hepatosteatosis and Adipocyte Hypertrophy in High Fat Diet-Fed Mice. | 2019 | Details |
| A11061 | 31062612 | Artif Cells Nanomed Biotechnol | Long non-coding RNA NEAT1 promotes steatosis via enhancement of estrogen receptor alpha-mediated AQP7 expression in HepG2 cells. | 2019 | Details |
| A11105 | 31040374 | Sci Rep | Metformin attenuates the onset of non-alcoholic fatty liver disease and affects intestinal microbiota and barrier in small intestine. | 2019 | Details |
| A11115 | 31035507 | Nutrients | Pterostilbene Reduces Liver Steatosis and Modifies Hepatic Fatty Acid Profile in Obese Rats. | 2019 | Details |
| A11117 | 31034714 | Mol Nutr Food Res | Pear Extract and Malaxinic Acid Reverse Obesity, Adipose Tissue Inflammation, and Hepatosteatosis in Mice. | 2019 | Details |
| A11132 | 31028903 | Pharmacol Res | Elafibranor restricts lipogenic and inflammatory responses in a human skin stem cell-derived model of NASH. | 2019 | Details |
| A11156 | 31019294 | Lab Invest | Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages. | 2019 | Details |
| A11164 | 31013988 | Nutrients | A Slow-Digesting Carbohydrate Diet during Rat Pregnancy Protects Offspring from Non-Alcoholic Fatty Liver Disease Risk through the Modulation of the Carbohydrate-Response Element and Sterol Regulatory Element Binding Proteins. | 2019 | Details |
| A11188 | 31007045 | Antioxid Redox Signal | Peroxiredoxin 6 Confers Protection Against Nonalcoholic Fatty Liver Disease Through Maintaining Mitochondrial Function. | 2019 | Details |
| A11234 | 30981986 | J Nutr Biochem | Western diet consumption through early life induces microvesicular hepatic steatosis in association with an altered metabolome in low birth weight Guinea pigs. | 2019 | Details |
| A11238 | 30978698 | J Mol Endocrinol | Humulus japonicus stimulates thermogenesis and ameliorates oxidative stress in mouse adipocytes. | 2019 | Details |
| A11247 | 30974975 | Hum Exp Toxicol | Aromatic aldehyde compound cuminaldehyde protects nonalcoholic fatty liver disease in rats feeding high fat diet. | 2019 | Details |
| A11256 | 30972177 | Am J Transl Res | Fetuin B aggravates liver X receptor-mediated hepatic steatosis through AMPK in HepG2 cells and mice. | 2019 | Details |
| A11265 | 30968772 | Curr Med Chem | Targeting n-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease. | 2020 | Details |
| A11304 | 30947882 | Clin Liver Dis | Obstructive Sleep Apnea and the Liver. | 2019 | Details |
| A11332 | 30935037 | Nutrients | Melatonin Improves Fatty Liver Syndrome by Inhibiting the Lipogenesis Pathway in Hamsters with High-Fat Diet-Induced Hyperlipidemia. | 2019 | Details |
| A11350 | 30927369 | Br J Pharmacol | Oral administration of a new HRI activator as a new strategy to improve high-fat-diet-induced glucose intolerance, hepatic steatosis, and hypertriglyceridaemia through FGF21. | 2019 | Details |